News
When Pharma Meets the Underworld: How Legitimate Drug Supply...
In today's global landscape, the intersection between legitimate pharmaceutical supply chains and illicit drug markets presents significant challenges. This confluence not only impacts public health...
News
Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare...
In the healthcare sector, the intersection of pharmaceutical companies and charitable organisations plays a pivotal role in enhancing global health outcomes. However, when these partnerships...
News
Role of Combination Products is on the Rise in...
In the dynamic world of today, role of combination products happens to be emerging as catalysts when it comes to transformative healthcare solutions. Defined widely...
News
Buyout of SpringWorks Brings Back Merck KGaA in the...
Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally come to a realization as the German drugmaker has purchased the Connecticut biopharma for an equity...
News
Roche Looks to Expand its Drug Production in the...
Roche is planning to expand its drug production in the US and has announced a pledge to spend $50 billion in the next five years...
News
How Language Barriers Impact Non-Native English Speakers in Healthcare
Language barriers create significant challenges for non-native English speakers in healthcare settings. In the United States, English is the primary language, which complicates communication for...
Clinical Trials
FDA Approval of AMVUTTRA for ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics, has announced U.S. FDA approval of AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy associated with wild-type...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.